Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Massimo Falconi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9654-7243; OpenAlex author ID A5053411917, A5057380925, A5159587617. Sources: OpenAlex.

Their work

Papers
158 (first author 3, last author 39)
Trials
0
Grants
0
Labs led
3
Collaborators
391
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 2 papers · 2014: 3 papers · 2015: 3 papers · 2016: 9 papers · 2017: 7 papers · 2018: 8 papers · 2019: 10 papers · 2020: 16 papers · 2021: 18 papers · 2022: 9 papers · 2023: 19 papers · 2024: 19 papers · 2025: 10 papers · 2026: 19 papers

Papers 50 of 158

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  3. Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. Co-author DOI 10.1002/ueg2.70179↗
  4. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  5. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  6. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Last author DOI 10.1007/s13304-026-02813-5↗
  7. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  8. Pancreatic adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in advanced pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.02.015↗
  9. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Last author DOI 10.1016/j.eclinm.2026.104190↗
  10. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  11. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Last author DOI 10.1016/s0140-6736(25)01685-x↗
  12. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  13. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  14. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  15. The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-25-4154↗
  16. Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial. Last author DOI 10.1186/s13063-026-09467-z↗
  17. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Last author DOI 10.1245/s10434-026-19218-8↗
  18. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Last author DOI 10.1245/s10434-026-19370-1↗
  19. ASO Author Reflections: Early Disease-Related Mortality After Neoadjuvant Therapy and Radical Resection for Pancreatic Ductal Adenocarcinoma-The Biological Bur… Last author DOI 10.1245/s10434-026-19400-y↗
  20. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  21. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  22. Association of Smoking with progression from low-risk to high-risk intraductal papillary mucinous neoplasms and pancreatic cancer. Co-author DOI 10.1016/j.dld.2024.05.017↗
  23. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Co-author DOI 10.1016/j.dld.2025.03.009↗
  24. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  25. Gastrointestinal symptoms in the journey of pancreatic cancer patients. Co-author DOI 10.1080/14737140.2025.2517888↗
  26. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Last author DOI 10.1093/bjsopen/zraf033↗
  27. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  28. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  29. Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. Last author DOI 10.1097/sla.0000000000006920↗
  30. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  31. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
  32. The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance… Co-author DOI 10.1007/s10689-024-00366-3↗
  33. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ctro.2024.100778↗
  34. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Co-author DOI 10.1016/j.dld.2023.07.006↗
  35. Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.07.033↗
  36. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
  37. Prognostic value of preoperative CT scan derived body composition measures in resected pancreatic cancer. Last author DOI 10.1016/j.ejso.2023.02.005↗
  38. Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis. Co-author DOI 10.1016/j.pan.2024.02.008↗
  39. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence. Last author DOI 10.1016/j.surg.2024.07.026↗
  40. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
  41. Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease. Co-author DOI 10.1053/j.seminoncol.2024.04.001↗
  42. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  43. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  44. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Co-author DOI 10.1097/sla.0000000000006166↗
  45. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  46. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition". Last author DOI 10.1245/s10434-024-15105-2↗
  47. ASO Author Reflections: Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: The Challenge of Minimal Residual Disease. Last author DOI 10.1245/s10434-024-15175-2↗
  48. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Last author DOI 10.14309/ajg.0000000000002546↗
  49. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  50. Multi-visceral resection for left-sided pancreatic ductal adenocarcinoma: a multicenter retrospective analysis from European countries. Co-author DOI 10.1007/s00423-023-03110-0↗

Closest collaborators

The 25 strongest of 391 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefano Crippa · 66 shared papers, 2011–2026 · strength 9.53
  2. Michele Reni · 66 shared papers, 2011–2026 · strength 8.42
  3. Giulio Belfiori · 38 shared papers, 2017–2026 · strength 6.63
  4. Gabriele Capurso · 36 shared papers, 2019–2026 · strength 5.90
  5. Paolo Giorgio Arcidiacono · 35 shared papers, 2016–2026 · strength 5.10
  6. Stefano Partelli · 41 shared papers, 2011–2026 · strength 4.98
  7. Domenico Tamburrino · 29 shared papers, 2011–2026 · strength 4.39
  8. Claudio Doglioni · 31 shared papers, 2016–2026 · strength 3.51
  9. Marina Macchini · 21 shared papers, 2018–2026 · strength 3.45
  10. Gianpaolo Balzano · 33 shared papers, 2016–2026 · strength 3.42
  11. Giuseppe Malleo · 20 shared papers, 2020–2026 · strength 3.28
  12. Nicolò Pecorelli · 17 shared papers, 2019–2026 · strength 3.20
  13. Roberto Salvia · 21 shared papers, 2013–2026 · strength 3.07
  14. Giulia Gasparini · 18 shared papers, 2019–2026 · strength 3.03
  15. Diego Palumbo · 16 shared papers, 2021–2026 · strength 3.01
  16. Lívia Archibugi · 18 shared papers, 2019–2026 · strength 2.96
  17. Marco Schiavo Lena · 17 shared papers, 2019–2026 · strength 2.94
  18. Giulia Orsi · 16 shared papers, 2020–2026 · strength 2.86
  19. Francesco DE COBELLI · 16 shared papers, 2020–2026 · strength 2.74
  20. Federico De Stefano · 10 shared papers, 2023–2026 · strength 2.28
  21. Gabriella Lionetto · 11 shared papers, 2023–2026 · strength 2.02
  22. Maria Chiara Petrone · 12 shared papers, 2019–2026 · strength 1.72
  23. Giovanni Guarneri · 10 shared papers, 2017–2026 · strength 1.69
  24. Salvatore Paiella · 10 shared papers, 2019–2026 · strength 1.67
  25. Fabio Casciani · 8 shared papers, 2024–2026 · strength 1.55

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.